Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers Meeting Abstract
| Authors: | Kris, M.; Goldberg, Z.; Jänne, P. A.; Kim, D.; Martins, R.; Mok, T. S. K.; O'Connell, J.; Ou, S.; Taylor, I.; Zhang, H. |
| Abstract Title: | Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers |
| Meeting Title: | 37th Congress of the European Society for Medical Oncology (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 23 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2012 Sep 28-Oct 2 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2012-09-01 |
| Start Page: | ix401 |
| End Page: | ix402 |
| Language: | English |
| ACCESSION: | WOS:000309409002164 |
| PROVIDER: | wos |
| PUBMED: | 23012731 |
| DOI: | 10.1093/annonc/mds409 |
| Notes: | Meeting Abstract: 1228O -- "Source: Wos" |
